Zeitschriftenartikel zum Thema „Y220C“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Y220C" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Gener-Ricos, Georgina, Jan Philipp Bewersdorf, Sanam Loghavi, Aaron D. Goldberg, Christopher Famulare, Ghayas C. Issa, Gautam Borthakur et al. „TP53 Y220C Mutations in Patients with Myeloid Malignancies“. Blood 142, Supplement 1 (28.11.2023): 1477. http://dx.doi.org/10.1182/blood-2023-189343.
Der volle Inhalt der QuelleCarter, Bing Z., Po Yee Mak, Baozhen Ke, Yuki Nishida, Steffen Boettcher, Andrea Bedoy, Lauren B. Ostermann et al. „Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2“. Blood 142, Supplement 1 (28.11.2023): 2261. http://dx.doi.org/10.1182/blood-2023-181186.
Der volle Inhalt der QuellePuzio-Kuter, Anna M., Chris Mulligan, Brandon Russo, Amy Wiebesiek, Lizhong Xu, Hong Yang, Binh Vu und Melissa Dumble. „Abstract 1295: Small molecule reactivators of Y220C mutant p53 modulate tumor infiltrating leukocytes and synergize with immune checkpoint inhibitors“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 1295. http://dx.doi.org/10.1158/1538-7445.am2022-1295.
Der volle Inhalt der QuelleZheng, Qian, Peng Wang, Chen Liang, Yao Li, Xin Sun, Amin Li, Wei Zhang, Wei Long und Yanping Wang. „Abstract 5940: JAB-30355: A highly potent, orally bioavailable p53-Y220C reactivator“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 5940. http://dx.doi.org/10.1158/1538-7445.am2024-5940.
Der volle Inhalt der QuelleLiu, Meng, Kaijun Geng, Biao Lu, Yuanfeng Xia und Fanglong Yang. „Abstract 7275: GS-P-328, a brain-penetrant small molecule p53 Y220C reactivator for tumors harboring p53 Y220C mutation“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 7275. http://dx.doi.org/10.1158/1538-7445.am2024-7275.
Der volle Inhalt der QuelleValenzuela-Chavira, Ignacio, Salvador Meneses-Sagrero, Aldo A. Arvizu-Flores, Javier Hernández-Paredes, Luisa Rascón-Valenzuela, Carlos A. Velázquez-Contreras und Ramón E. Robles-Zepeda. „Molecular Docking of the Cardenolides of Asclepias subulata in the Human p53 Protein Reveals an Interaction in the Cleft of the Y220C Mutant“. Current Chemical Biology 15, Nr. 3 (September 2021): 222–33. http://dx.doi.org/10.2174/2212796815666211026112056.
Der volle Inhalt der QuelleBauer, Matthias R., Rhiannon N. Jones, Raysa K. Tareque, Bradley Springett, Felix A. Dingler, Lorena Verduci, Ketan J. Patel, Alan R. Fersht, Andreas C. Joerger und John Spencer. „A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C“. Future Medicinal Chemistry 11, Nr. 19 (Oktober 2019): 2491–504. http://dx.doi.org/10.4155/fmc-2019-0181.
Der volle Inhalt der QuelleBaud, Matthias G. J., Matthias R. Bauer, Lorena Verduci, Felix A. Dingler, Ketan J. Patel, Deeptee Horil Roy, Andreas C. Joerger und Alan R. Fersht. „Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines“. European Journal of Medicinal Chemistry 152 (Mai 2018): 101–14. http://dx.doi.org/10.1016/j.ejmech.2018.04.035.
Der volle Inhalt der QuelleSchram, Alison M., Geoffrey I. Shapiro, Melissa L. Johnson, Anthony W. Tolcher, John A. Thompson, Anthony B. El-Khoueiry, Andrae L. Vandross et al. „Abstract LB_A25: Updated Phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation“. Molecular Cancer Therapeutics 22, Nr. 12_Supplement (01.12.2023): LB_A25. http://dx.doi.org/10.1158/1535-7163.targ-23-lb_a25.
Der volle Inhalt der QuelleLane, David P., und Chandra S. Verma. „Covalent Rescue of Mutant p53“. Cancer Discovery 13, Nr. 1 (09.01.2023): 14–16. http://dx.doi.org/10.1158/2159-8290.cd-22-1212.
Der volle Inhalt der QuelleRockwell, Nathan, Nicole Warrington und Joshua Rubin. „CBIO-22. p53 GAIN-OF-FUNCTION MUTATIONS DRIVE SEX SPECIFIC EFFECTS ON GLIOMA TUMORIGENESIS“. Neuro-Oncology 22, Supplement_2 (November 2020): ii20. http://dx.doi.org/10.1093/neuonc/noaa215.082.
Der volle Inhalt der QuelleGomes, Sara, Bartolomeo Bosco, Joana B. Loureiro, Helena Ramos, Liliana Raimundo, Joana Soares, Nair Nazareth et al. „SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma“. Cancers 11, Nr. 8 (10.08.2019): 1151. http://dx.doi.org/10.3390/cancers11081151.
Der volle Inhalt der QuelleGori, M., B. Barbaro, R. Maggio, M. Arciello, C. Viscomi und C. Balsano. „Protective effect of the Y220C mutant p53 during steatosis: Good news?“ Digestive and Liver Disease 45 (Oktober 2013): e368-e369. http://dx.doi.org/10.1016/j.dld.2013.09.010.
Der volle Inhalt der QuelleMiller, Jessica J., Christophe Orvain, Shireen Jozi, Ryan M. Clarke, Jason R. Smith, Anaïs Blanchet, Christian Gaiddon, Jeffrey J. Warren und Tim Storr. „Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer“. Chemistry - A European Journal 24, Nr. 67 (09.11.2018): 17734–42. http://dx.doi.org/10.1002/chem.201802677.
Der volle Inhalt der QuelleGori, Manuele, Barbara Barbaro, Mario Arciello, Roberta Maggio, Carmela Viscomi, Alessia Longo und Clara Balsano. „Protective Effect of the Y220C Mutant p53 Against Steatosis: Good News?“ Journal of Cellular Physiology 229, Nr. 9 (23.05.2014): 1182–92. http://dx.doi.org/10.1002/jcp.24550.
Der volle Inhalt der QuelleGori, M., B. Barbaro, M. Arciello, R. Maggio, C. Viscomi, A. Longo und C. Balsano. „Protective Effect of the Y220C Mutant p53 Against Steatosis: Good News?“ Journal of Cellular Physiology 230, Nr. 6 (25.02.2015): 1400. http://dx.doi.org/10.1002/jcp.24874.
Der volle Inhalt der QuelleDixit, Updesh, Ashutosh K. Pandey, Zhihe Liu, Sushil Kumar, Matthew B. Neiditch, Kenneth M. Klein und Virendra N. Pandey. „FUSE Binding Protein 1 Facilitates Persistent Hepatitis C Virus Replication in Hepatoma Cells by Regulating Tumor Suppressor p53“. Journal of Virology 89, Nr. 15 (20.05.2015): 7905–21. http://dx.doi.org/10.1128/jvi.00729-15.
Der volle Inhalt der QuelleGener-Ricos, Georgina, Koji Sasaki, Sanam Loghavi, Abhishek Maiti, Nicholas Short, Fadi Haddad, Naval Daver et al. „A Descriptive Analysis of TP53 Y220C Mutations in Patients with Hematologic Malignancies“. Blood 140, Supplement 1 (15.11.2022): 11830–32. http://dx.doi.org/10.1182/blood-2022-167923.
Der volle Inhalt der QuelleRauf, Shah Md Abdur, Akira Endou, Hiromitsu Takaba und Akira Miyamoto. „Effect of Y220C Mutation on p53 and Its Rescue Mechanism: A Computer Chemistry Approach“. Protein Journal 32, Nr. 1 (Januar 2013): 68–74. http://dx.doi.org/10.1007/s10930-012-9458-x.
Der volle Inhalt der QuelleSHEN, Hong-Chen, Ji-Yong DING, Li LI und Fu-Feng LIU. „Effect of Y220C Mutant on the Conformational Transition of p53C Probed by Molecular Dynamics Simulation“. Acta Physico-Chimica Sinica 32, Nr. 10 (2016): 2620–27. http://dx.doi.org/10.3866/pku.whxb201606224.
Der volle Inhalt der Quellevan Kempen, Pauline M. W., Froukje J. Verdam, Eyleen de Poel, Weibel W. Braunius, Roel A. de Weger, Robert J. J. van Es, Wilko Grolman und Stefan M. Willems. „TP53 Y220C Is a Hotspot Mutation in Oropharyngeal Squamous Cell Carcinoma“. Pathobiology 82, Nr. 1 (2015): 21–27. http://dx.doi.org/10.1159/000369102.
Der volle Inhalt der QuelleKhadiullina, Raniya, Regina Mirgayazova, Damir Davletshin, Elvina Khusainova, Vitaly Chasov und Emil Bulatov. „Assessment of Thermal Stability of Mutant p53 Proteins via Differential Scanning Fluorimetry“. Life 13, Nr. 1 (22.12.2022): 31. http://dx.doi.org/10.3390/life13010031.
Der volle Inhalt der QuelleBauer, Matthias R., Rhiannon N. Jones, Matthias G. J. Baud, Rainer Wilcken, Frank M. Boeckler, Alan R. Fersht, Andreas C. Joerger und John Spencer. „Harnessing Fluorine–Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs“. ACS Chemical Biology 11, Nr. 8 (21.06.2016): 2265–74. http://dx.doi.org/10.1021/acschembio.6b00315.
Der volle Inhalt der QuelleAccordino, Sebastián R., J. Ariel Rodríguez Fris und Gustavo A. Appignanesi. „Wrapping Effects within a Proposed Function-Rescue Strategy for the Y220C Oncogenic Mutation of Protein p53“. PLoS ONE 8, Nr. 1 (24.01.2013): e55123. http://dx.doi.org/10.1371/journal.pone.0055123.
Der volle Inhalt der QuelleBasse, Nicolas, Joel L. Kaar, Giovanni Settanni, Andreas C. Joerger, Trevor J. Rutherford und Alan R. Fersht. „Toward the Rational Design of p53-Stabilizing Drugs: Probing the Surface of the Oncogenic Y220C Mutant“. Chemistry & Biology 17, Nr. 1 (Januar 2010): 46–56. http://dx.doi.org/10.1016/j.chembiol.2009.12.011.
Der volle Inhalt der QuelleShokat, Kevan M. „Abstract IA08: Direct covalent inhibitors of mutant K-Ras“. Molecular Cancer Research 21, Nr. 5_Supplement (01.05.2023): IA08. http://dx.doi.org/10.1158/1557-3125.ras23-ia08.
Der volle Inhalt der QuelleYu, Camilla, Aaron Petty und Roberto Vargas. „Abstract 4885: APR-246 cytotoxic effects are TP53 independent in endometrial cancer cell lines“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 4885. http://dx.doi.org/10.1158/1538-7445.am2023-4885.
Der volle Inhalt der QuelleAhire, Vidhula, D. Das, Kaushala Prasad Mishra, G. R. Kulkarni und L. Ackland. „Inhibition of the p53 Y220C Mutant by 1-Hydroxy-2- Methylanthraquinone Derivatives: A Novel Strategy for Cancer Therapy“. Journal of Environmental Pathology, Toxicology and Oncology 35, Nr. 4 (2016): 355–64. http://dx.doi.org/10.1615/jenvironpatholtoxicoloncol.2016012256.
Der volle Inhalt der QuelleBromley, Dennis, Matthias R. Bauer, Alan R. Fersht und Valerie Daggett. „Anin silicoalgorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein“. Protein Engineering Design and Selection 29, Nr. 9 (08.08.2016): 377–90. http://dx.doi.org/10.1093/protein/gzw035.
Der volle Inhalt der QuelleLuparello, Claudio, Ilenia Cruciata, Andreas C. Joerger, Cory A. Ocasio, Rhiannon Jones, Raysa Khan Tareque, Mark C. Bagley et al. „Genotoxicity and Epigenotoxicity of Carbazole-Derived Molecules on MCF-7 Breast Cancer Cells“. International Journal of Molecular Sciences 22, Nr. 7 (26.03.2021): 3410. http://dx.doi.org/10.3390/ijms22073410.
Der volle Inhalt der QuelleBhuvaneshwari, C., und S. Ambiga. „Antioxidant and anticancer activities of Solanum nigrum Linn leaves“. Journal of Current Opinion in Crop Science 3, Nr. 2 (28.06.2022): 79–89. http://dx.doi.org/10.62773/jcocs.v3i2.171.
Der volle Inhalt der QuelleArciello, Mario, Alessia Longo, Carmela Viscomi, Concetta Capo, Antonio Angeloni, Luisa Rossi und Clara Balsano. „Core domain mutant Y220C of p53 protein has a key role in copper homeostasis in case of free fatty acids overload“. BioMetals 28, Nr. 6 (05.10.2015): 1017–29. http://dx.doi.org/10.1007/s10534-015-9886-0.
Der volle Inhalt der QuelleTseng, Tsui-Hwa, Chau-Jong Wang, Yean-Jang Lee, Yi-Chia Shao, Chien-Heng Shen, Ko-Chao Lee, Shui-Yi Tung und Hsing-Chun Kuo. „Suppression of the Proliferation of Huh7 Hepatoma Cells Involving the Downregulation of Mutant p53 Protein and Inactivation of the STAT 3 Pathway with Ailanthoidol“. International Journal of Molecular Sciences 23, Nr. 9 (04.05.2022): 5102. http://dx.doi.org/10.3390/ijms23095102.
Der volle Inhalt der QuelleTseng, Tsui-Hwa, Yi-Chia Shao, Yean-Jang Lee und Huei-Jane Lee. „2-(4-Benzyloxy-3-methoxyphenyl)-5-(carbethoxyethylene)-7-methoxy-benzofuran, a Benzofuran Derivative, Suppresses Metastasis Effects in P53-Mutant Hepatocellular Carcinoma Cells“. Biomedicines 11, Nr. 7 (19.07.2023): 2027. http://dx.doi.org/10.3390/biomedicines11072027.
Der volle Inhalt der QuelleLv, Cuiting, Aihua Lan, Xiao Fan, Caiguo Huang und Gong Yang. „Asperolide A induces apoptosis and cell cycle arrest of human hepatoma cells with p53-Y220C mutant through p38 mediating phosphorylation of p53 (S33)“. Heliyon 9, Nr. 3 (März 2023): e13843. http://dx.doi.org/10.1016/j.heliyon.2023.e13843.
Der volle Inhalt der QuelleCheng, Ya-Yun, Denise Prosser, Liudmila Velikokhatnaya und Anna Lokshin. „Abstract 5833: Functional characterization of TP53 mutations in human fallopian tube secretory epithelial cells“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 5833. http://dx.doi.org/10.1158/1538-7445.am2022-5833.
Der volle Inhalt der QuellePetty, Aaron, Arda Durmaz, Brian Yard, Jacob Scott und Roberto Vargas. „Abstract 1090: Dominant-negative TP53 variants confer radiation resistance in endometrial cancer“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 1090. http://dx.doi.org/10.1158/1538-7445.am2023-1090.
Der volle Inhalt der QuelleYang, Yaxian, Heran Wang, Lucas Wang, WenTao Fan, Bin Lian, Ying Jin, Weiquan Luo et al. „Frequency and patterns of TP53 mutations in lung cancer.“ Journal of Clinical Oncology 41, Nr. 16_suppl (01.06.2023): e21013-e21013. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e21013.
Der volle Inhalt der QuelleBabatunde, Olayode, Ryan Quin Notti und William D. Tap. „Characterizing TP53 mutations in bone and soft tissue sarcoma.“ Journal of Clinical Oncology 42, Nr. 16_suppl (01.06.2024): e23521-e23521. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e23521.
Der volle Inhalt der QuelleMoses, Renyta, Ryan Hausler, Gregory Kelly, Alexandra Indeglia, Sven Miller, John Karanicolas, Maureen Murphy und Kara Maxwell. „Abstract 3025: Germline p53 R181 variants and DNA binding cooperativity in tumorigenesis“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 3025. http://dx.doi.org/10.1158/1538-7445.am2024-3025.
Der volle Inhalt der QuelleNesline, Mary K., Paul DePietro, Maureen Cooper, Shengle Zhang, Sarah Howarth, Zachary D. Wallen, Michael D. Biorn et al. „The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program.“ Journal of Clinical Oncology 41, Nr. 16_suppl (01.06.2023): 6506. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.6506.
Der volle Inhalt der QuelleBattaglin, Francesca, Andrew Elliott, Joanne Xiu, Sandra Algaze, Jingyuan Wang, Priya Jayachandran, Shivani Soni et al. „Identification and characterization of immunogenic neoantigens in biliary cancer (BC) and pancreatic cancer (PC).“ Journal of Clinical Oncology 42, Nr. 3_suppl (20.01.2024): 552. http://dx.doi.org/10.1200/jco.2024.42.3_suppl.552.
Der volle Inhalt der QuelleSteinbuck, Martin P., Xavier Cabana-Puig, Erica Palmer, Mimi M. Jung, Thomas Williams, Kristen Osaer, Jeff Zhang, Christopher M. Haqq und Peter C. DeMuth. „Abstract 4099: AMP-peptide vaccination against multiple p53 mutant epitopes promotes lymph node delivery to generate potent, functional T cell immunity“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 4099. http://dx.doi.org/10.1158/1538-7445.am2024-4099.
Der volle Inhalt der QuelleSuehnholz, Sarah P., Moriah Nissan, Hongxin Zhang, Ritika Kundra, Calvin Lu, Amanda Dhaneshwar, Nicole Fernandez et al. „Abstract 6585: OncoKB, MSK’s precision oncology knowledge base“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 6585. http://dx.doi.org/10.1158/1538-7445.am2023-6585.
Der volle Inhalt der QuelleKim, Peter, Parisa Malekzadeh, Nolan Vale, Elizabeth Hedges, Nikolaos Zacharakis und Steven Rosenberg. „152 Adoptive T cell therapy targeting somatic p53 mutations“. Journal for ImmunoTherapy of Cancer 8, Suppl 3 (November 2020): A165—A166. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0152.
Der volle Inhalt der QuelleVan Alsten, Sarah, Ebonee Butler, Benjamin Calhoun, Michael Love, Charles Perou, Katherine A. Hoadley und Melissa Troester. „Abstract PO1-08-12: Genomic Characterization of the Carolina Breast Cancer Study“. Cancer Research 84, Nr. 9_Supplement (02.05.2024): PO1–08–12—PO1–08–12. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-08-12.
Der volle Inhalt der QuelleDeb, S., S. Bandyopadhyay und S. Roy. „Spectroscopic study of Y210C lambda-repressor: implications for cooperative interaction“. Protein Engineering Design and Selection 11, Nr. 6 (01.06.1998): 481–87. http://dx.doi.org/10.1093/protein/11.6.481.
Der volle Inhalt der QuelleДемидова, Т. Е., И. Н. Чижевская und А. Е. Чижевский. „Formation of historical memory of students by means of network project activities“. Management of Education 14, Nr. 1-1(74) (15.01.2024): 165–74. http://dx.doi.org/10.25726/y2202-2949-1521-f.
Der volle Inhalt der QuelleBauer, Matthias R., Andreas Krämer, Giovanni Settanni, Rhiannon N. Jones, Xiaomin Ni, Raysa Khan Tareque, Alan R. Fersht, John Spencer und Andreas C. Joerger. „Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm“. ACS Chemical Biology 15, Nr. 3 (28.01.2020): 657–68. http://dx.doi.org/10.1021/acschembio.9b00748.
Der volle Inhalt der QuelleCarter, Bing Z., Po Yee Mak, Wenjing Tao, Lauren B. Ostermann, Steffen Boettcher, Yuki Nishida, Edward Ayoub et al. „Combined Inhibition of Bcl-2 and Mcl-1 Circumvents Resistance of TP53 Deficient/Mutant AML to BH3 Mimetics“. Blood 138, Supplement 1 (05.11.2021): 2239. http://dx.doi.org/10.1182/blood-2021-148014.
Der volle Inhalt der Quelle